TONIC: Cognitive Stimulation for Elderly Bipolar Patients

Sponsor
Groupe Hospitalier de la Rochelle Ré Aunis (Other)
Overall Status
Recruiting
CT.gov ID
NCT04184375
Collaborator
(none)
40
1
2
30.1
1.3

Study Details

Study Description

Brief Summary

Age is a major risk factor for the development of cognitive disorders and neurodegenerative pathologies. Cognitive disorders during the phases of bipolar disease are known to exist, and alterations increase significantly after the age of 65. Drug treatments seem to have only a limited effect. A cognitive stimulation program has proven his benefit to patients over 65 with neurodegenerative diseases (Israel, 2004). We propose to evaluate this cognitive stimulation program that we have adapted to bipolar disease.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: cognitive stimulation
N/A

Detailed Description

Bipolar disorders, which belong to the category of mood disorders, are the 6th leading cause of disability in the world. Cognitive disorders are known to exist during the phases of bipolar disease, and alterations increase significantly after the age of 65. Recent studies have shown that attention, memory and executive function impairments are the main causes of cognitive disorders. Residual symptoms have a significant impact on the risk of relapse into bipolar disorder and on quality of life. Cognitive stimulation (CS) is a pedagogical approach based on the idea that cognitive skills contribute to personal development in the same way as psychological and social factors. This study aims at assessing a cognitive stimulation program initially developed for patients with neurodegenerative diseases, and adapted to bipolar disease. This program will be compared to the usual practice consisting in consultation with psychiatrist and sometimes in intervention of home nurses.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Evaluation of Cognitive Stimulation on Dysexecutive Residual Symptoms in Bipolar Patients Over 65 Years of Age
Actual Study Start Date :
Sep 10, 2020
Anticipated Primary Completion Date :
Dec 15, 2022
Anticipated Study Completion Date :
Mar 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: TONIC

The cognitive stimulation sessions are carried out using Liliane Israël's "TRAIN YOUR MEMORY" software, and are divided into two parts: the first part is essentially cognitive and the second relates to the daily life of the Bipolar patient. This training method consists of combining two means of intervention, pedagogical action and psychotherapeutic effect. It aims to stimulate, develop and strengthen the basic mechanisms underlying memory phenomena (sensory acuity, attention, associations, structuring, executive functions, spatial and temporal landmarks, associative recruitment). It is presented in the form of exercises divided into eight modules.

Behavioral: cognitive stimulation
Patients participate in one session per week according to the following schedule: 2 sensory stimulation sessions: identify sensations, emotions, how to manage them. 2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness. 2 voluntary attention sessions: improve daily attention. 2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities. 2 sessions of structuring through language: impact on social life. 2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips.

No Intervention: Control

The usual practice consists of interviews with the psychiatrist with the possibility of home visits by the nurse.

Outcome Measures

Primary Outcome Measures

  1. Score at the Frontal Assessment Battery (FAB) [at 3 months after inclusion]

    The FAB assesses conceptualization (category responses, such as "in what way are a banana and an orange are alike?"), lexical fluency, programming or motor series (Luria), sensitivity to interference (conflicting instructions, such as "tap twice when I tap once"), inhibitory control (Go/No-Go), and environmental autonomy (prehension behavior, such as "do not take my hands")

Secondary Outcome Measures

  1. Score at FAB [at 6 months after inclusion]

    Scores between the 3-month and 6-month evaluation will determine whether executive analysis functions have been maintained

  2. Number of patients with a positive difference between the scores on the Functional Activities Questionnaire (QAF) [at inclusion]

    The QAF allows to quickly assess a patient's functional capacity and to identify a functional decline in the patient with a mild neurocognitive disorder, Alzheimer's disease or other neurocognitive disorder.

  3. Number of patients with a positive difference between the scores on the Functional Activities Questionnaire (QAF) [at 6 months after inclusion]

    A positive difference in scores reflects an improvement in patient autonomy

  4. Score at delayed matching-to-sample (DMS48) [at inclusion]

    The DMS48 is a test of visual recognition memory test

  5. Score at DMS48 [at 3 months after inclusion]

    The DMS48 is a test of visual recognition memory test

  6. Time in minutes at the Trail Making Test A (TMTA) [at inclusion]

    Evaluation of speed of processing.

  7. Time in minutes at the Trail Making Test A [at 3 months after inclusion]

    Evaluation of speed of processing.

  8. Number of errors at Trail Making Test B (TMTB) [at inclusion]

    Evaluation of mental flexibility

  9. Number of errors at Trail Making Test B (TMTB) [at 3 months after inclusion]

    Evaluation of mental flexibility

  10. Score at ISAAC test [at inclusion]

    Measures fluence

  11. Score at ISAAC test [at 3 months after inclusion]

    Measures fluence

  12. Score at Montreal Cognitive Assessment (MMS) [at inclusion]

    Assessment for detecting cognitive impairment

  13. Score at Montreal Cognitive Assessment (MMS) [at 6 months after inclusion]

    Assessment for detecting cognitive impairment

  14. Score at the Hamilton Depression Rating Scale [at inclusion]

    Evaluation of patient thymic state

  15. Score at the Hamilton Depression Rating Scale [at 6 months after inclusion]

    Evaluation of patient thymic state

  16. Interference score at the Stroop test [at inclusion]

    Evaluation of selective attention

  17. Interference score at the Stroop test [at 6 months after inclusion]

    Evaluation of selective attention

  18. Number of hospitalization due to relapse [at 6 months after inclusion]

    hospitalization due to relapse

  19. Score at Zarit scale (caregiver) [at inclusion]

    Identification of suffering or exhaustion, anxiety and/or depressive disorder(s), sleep disorder(s), etc. in the caregiver

  20. Score at Zarit scale (caregiver) [at 6 months after inclusion]

    Identification of suffering or exhaustion, anxiety and/or depressive disorder(s), sleep disorder(s), etc. in the caregiver

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Pre-Inclusion Criteria:
  • age > 65 years old

  • Diagnosis of bipolar illness for more than 10 years

  • Euthymic phase

  • Understands and speaks French

  • Free, informed and express consent

Inclusion Criteria:
  • Mild to moderate neuro-cognitive impairments (MMS Test : 16 ≤ score < 26)
Exclusion Criteria:
  • Illiteracy

  • Patient participating in other therapeutic workshops (e. g. psycho-geriatric day hospital care, etc.)

  • Persons deprived of their liberty by a judicial or administrative decision

  • Persons of full age who are subject to a legal protection measure

  • Persons unable to consent

  • Persons who are not members of or beneficiaries of a social security scheme

  • Patient's refusal to participate in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Groupe Hospitalier de la Rochelle Ré Aunis La Rochelle France

Sponsors and Collaborators

  • Groupe Hospitalier de la Rochelle Ré Aunis

Investigators

  • Study Director: Pascale Puzos, MD, Groupe Hospitalier de la Rochelle Ré Aunis

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Groupe Hospitalier de la Rochelle Ré Aunis
ClinicalTrials.gov Identifier:
NCT04184375
Other Study ID Numbers:
  • 2015/P05/095
First Posted:
Dec 3, 2019
Last Update Posted:
Jan 24, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 24, 2022